DJIA 16,009.24 -17.81 -0.11%
NASDAQ 4,267.08 -16.68 -0.39%
S&P 500 1,852.21 -1.23 -0.07%
market minute promo

8.02 -0.12 (-1.47%)

REAL-TIME: Last trade at

Extended Hours: $8.02 $0.00 (0.00%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

LXRX $8.02 -1.47%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $7.99
Previous Close $8.14
Daily Range $7.70 - $8.27
52-Week Range $6.06 - $15.79
Market Cap $831.1M
P/E Ratio -9.15
Dividend (Yield) $0.00 (0.0%)
Volume 931,222
Average Daily Volume 578,399
Current FY EPS -$1.29

Sector

Healthcare

Industry

Drug Makers

Lexicon Pharmaceuticals, Inc. (LXRX) Description

A biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Website: http://www.lexpharma.com/

News & Commentary Rss Feed

These Secret Ingredients Led Lexicon Pharmaceuticals, Inc. Up 109% in 2015

Look no further than these two catalysts as to why Lexicon Pharmaceuticals more than doubled in 2015.

The Lullaby Portfolio

Commit To Buy Lexicon Pharmaceuticals At $7.50, Earn 22.6% Annualized Using Options

Oversold Conditions For Lexicon Pharmaceuticals (LXRX)

Every Biotech Catalyst Wedbush Is Watching In 2016

15 Best Stocks to Ring Out the Old, Ring In the New

Top Biotech Stocks to Buy in 2016

Our Motley Fool contributors named these three biotech stocks as their top ideas heading into 2016.

Lexicon Reveals Positive Data on Carcinoid Syndrome Drug

Lexicon Pharmaceuticals: Promising Small Cap Has 50% Upside

Telotristat Etiprate Achieves Positive Top-Line Results In Second Phase 3 Clinical Trial, Met Primar

Telotristat Etiprate Achieves Positive Top-Line Results In Second Phase 3 Clinical Trial, Met Primary Endpoint

See More LXRX News...

LXRX's Top Competitors

LXRX $8.02 (-1.47%)
Current stock: LXRX
GILD $87.23 (2.31%)
Current stock: GILD
AMGN $143.16 (0.11%)
Current stock: AMGN
BIIB $249.99 (-0.31%)
Current stock: BIIB